Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of NVX-CoV2373 in Healthy Subjects
NCT04368988Phase 2Completed
- Sponsor
- Novavax
- Start
- May 2020
- Primary completion
- Jun 2022
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
A Phase 2 trial of NVX-CoV2373 in coronavirus disease 2019 (COVID-19), sponsored by Novavax. Started May 2020; status: completed.
02
Drugs
NVX-CoV2373
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04368988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04368988.